Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
Go back to Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment| Gilead Sciences (NASDAQ: GILD) | Delayed: 123.76 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $123.76 | 52 Week High | $108.63 | |||
| Open | $123.76 | 52 Week Low | $71.39 | |||
| Day High | $123.76 | P/E | 68.38 | |||
| Day Low | $123.76 | EPS | $1.81 | |||
| Volume | 3,188 | |||||
| Merck & Co. (NYSE: MRK) | Delayed: 113.87 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $113.87 | 52 Week High | $65.46 | |||
| Open | $113.87 | 52 Week Low | $47.97 | |||
| Day High | $113.87 | P/E | 77.46 | |||
| Day Low | $113.87 | EPS | $1.47 | |||
| Volume | 52,469 | |||||
